IgA vasculitis (formerly Henoch-Schönlein purpura) — the most common systemic vasculitis in children affecting approximately 10-20 per 100,000 annually, with up to 50% of patients experiencing persistent renal involvement requiring long-term immunosuppression — creates the most clinically dynamic segment in the broader vasculitis treatment landscape, with the Immunoglobulin A IgA Vasculitis Market reflecting the transition from corticosteroid-dependent management to precision biologic intervention.

The pediatric vasculitis biologics evolution — the therapeutic shift where rituximab (anti-CD20 monoclonal antibody) and tocilizumab (anti-IL-6 receptor antagonist) demonstrate efficacy in refractory IgA vasculitis with nephritis, alongside emerging JAK inhibitor (tofacitinib, baricitinib) and complement pathway inhibitor (eculizumab) investigations — demonstrates the precision medicine approach replacing empirical immunosuppression. The ACR/EULAR classification criteria now distinguishing IgA vasculitis from other small-vessel vasculitides enabling more targeted clinical trial enrollment and biomarker-driven patient selection.

Renal-sparing treatment protocols — the clinical innovation creating individualized immunosuppression strategies (mycophenolate mofetil, azathioprine, calcineurin inhibitors) for persistent proteinuria and crescentic glomerulonephritis — represents the organ-specific approach transforming outcomes. The KDIGO guidelines recommending renin-angiotensin system blockade as first-line nephroprotection, with escalation to immunosuppression based on histological ISKDC grade, demonstrates the risk-stratified management reducing progression to end-stage renal disease.

Adult-onset IgA vasculitis recognition — the growing awareness that approximately 30% of cases occur in adults with more severe systemic involvement, higher relapse rates, and distinct therapeutic response patterns — creates the demographic expansion beyond the historically pediatric-focused treatment paradigm. Adult patients' increased likelihood of requiring combination immunosuppression and experiencing gastrointestinal, pulmonary, and neurological complications driving the demand for specialized vasculitis center referral.

Do you think complement-targeted therapies (C5a inhibitors, factor B inhibitors) will emerge as the preferred approach for severe IgA vasculitis nephritis, or will B-cell depletion strategies maintain dominance in the refractory setting?

What are the current treatment options for IgA vasculitis with renal involvement? Standard management: supportive care for mild cutaneous/gastrointestinal disease; corticosteroids (prednisone 1-2 mg/kg/day) for severe systemic symptoms; renal-limited disease: ACE inhibitors/ARBs for proteinuria >0.5 g/day; immunosuppression escalation: mycophenolate mofetil (2 g/day), azathioprine (2 mg/kg/day), cyclophosphamide (oral or IV pulses) for crescentic nephritis; biologics: rituximab (375 mg/m² weekly × 4, or 1g × 2) for refractory disease; tocilizumab (8 mg/kg IV monthly) for IL-6 driven inflammation; emerging: JAK inhibitors (tofacitinib 5mg BID), eculizumab (complement C5 inhibitor) for severe complement-mediated disease; KDIGO guidelines: renin-angiotensin blockade first-line; histology-driven immunosuppression for ISKDC grades III-V; prognosis: 1-5% progression to ESRD in children, higher in adults with crescentic disease.

How does the IgA vasculitis market fit into the broader vasculitis treatment landscape? Market context: subset of global vasculitis treatment market projected at USD 3.5 billion (2026) growing to USD 5.2 billion (2033) at 5.5% CAGR; corticosteroids dominant (55% share) but biologics fastest-growing (40% of prescriptions, expanding); IgA vasculitis-specific drivers: pediatric prevalence creating sustained demand; renal complication management requiring long-term therapy; biologics adoption in refractory cases; unmet need: no FDA-approved therapy specifically for IgA vasculitis; all treatments off-label or guideline-based; competitive landscape: Roche (rituximab), Genentech (tocilizumab), Pfizer (tofacitinib), AstraZeneca (eculizumab); clinical trial activity: limited due to rarity and pediatric focus; regional distribution: North America 45%, Europe 30%, Asia-Pacific 18%; growth factors: improved diagnostic awareness, biomarker development (galactose-deficient IgA1), pediatric rheumatology specialization.

#IgAVasculitis #HenochSchonleinPurpura #PediatricVasculitis #Rituximab #VasculitisTreatment #BiologicsInRheumatology #IgANephropathy #RareDisease